Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

3(75%)

Phase Distribution

Ph phase_3

50%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

2(50.0%)

Phase 3Large-scale testing

2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (50.0%)

Phase 32 (50.0%)

Trials by Status

completed125%

terminated375%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_3

Study of TV-1106 in Growth Hormone-Deficient Adults

NCT02410343

completedphase_2

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

NCT01811576

terminatedphase_3

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

NCT02410356

terminatedphase_2

A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children

NCT02092077

Clinical Trials (4)

Showing 4 of 4 trials

NCT02410343Phase 3

Study of TV-1106 in Growth Hormone-Deficient Adults

Terminated

NCT01811576Phase 2

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

Completed

NCT02410356Phase 3

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

Terminated

NCT02092077Phase 2

A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4